DeuteRx CEO Honored with Two Industry Awards for Entrepreneurial Success and Innovation in Biopharma R&D
Lead preclinical program, DRX-184 (d-S-bupropion), granted new US patent with term to May 2044.
BOSTON, April 23, 2025 /PRNewswire/ -- DeuteRx, LLC, a biopharmaceutical company developing novel small molecule therapeutics, today announced that Chair, President, and CEO Sheila DeWitt, PhD, has been honored with two prestigious industry awards recognizing her groundbreaking contributions as a leader in drug discovery and biopharma entrepreneurship.
Dr. DeWitt was awarded the 2025 Kathryn C. Hach Award for Entrepreneurial Success by the American Chemical Society (ACS) for her achievements in deuterium-enabled therapeutics, microfluidics, and combinatorial chemistry. She accepted the award and delivered a lecture, "Reactions to Failure: Catalysts to My Success as a Drug Discovery Entrepreneur," at the ACS Spring Meeting in San Diego on March 23, 2025 (MEDI 4198051). Dr. DeWitt will receive her second award, the 2025 Gertrude Elion Medicinal Chemistry Award, at the ACS Fall Meeting in Washington, DC, on August 17. These two honors celebrate the legacies of trailblazers Kathryn Hach-Darrow and Gertrude Elion, and spotlight Dr. DeWitt's 35-year track record of innovation and leadership in pharma R&D.
"It is a tremendous honor to receive these awards that recognize the groundbreaking work of two exceptional women, Kathryn (Kitty) Hach-Darrow and Gertrude Elion. While these awards reflect my individual achievements, they also pay tribute to the exceptional contributions of the colleagues and collaborators that I have had the opportunity to work with over my career as a scientist and business leader," states Dr. DeWitt.
"Sheila's entrepreneurial achievements are vast in scope," said Dr. Bruce Ganem, Franz and Elisabeth Roessler Professor, Cornell University. "She has led the start-up or turnaround of nine biotechnology companies or business units and managed global R&D organizations with annual budgets of up to $30 million."
A recognized pioneer in deuterated drug development, Dr. DeWitt invented Deuterium-Enabled Chiral Switching (DECS), a unique approach to create new chemical entities (NCEs) with composition of matter patent protection and the potential for expedited and derisked drug development versus traditional R&D. Using deuterium to stabilize and characterize the desired stereoisomer provides a never-before-realized opportunity to deliver a superior therapeutic with improved efficacy or tolerability for patients. Under her leadership, the team has completed three M&A transactions and advanced a pipeline of over 10 deuterated drug candidates from preclinical to Phase 2.
DeuteRx is advancing several drug candidates including first-in-class NCEs for psychiatric, neuromuscular, dermatology, anti-infective, cardiorenal, and oncology indications. The lead program, deuterium-stabilized bupropion (DRX-184), is being advanced for major depressive disorder (MDD) with anhedonia. The compound was recently granted U.S. Patent 12,180,137, securing protection through at least May 2044.
About DeuteRx, LLCDeuteRx is a privately held biopharmaceutical company dedicated to developing differentiated new medicines with improved therapeutic profiles for patients. The company has pioneered DECS (deuterium-enabled chiral switching) to create differentiated NCEs with new composition of matter patent protection and the potential for an expedited and derisked development path. Success to date includes 3 M&A transactions, a Phase 2b NASH drug candidate (PXL065 in collaboration with Poxel SA), remarkable discoveries with DECS, and >50 issued patents.
For more information visit DeuteRx.com
DeuteRx Contact: info@deuterx.com Investors: mwallace@deuterx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/deuterx-ceo-honored-with-two-industry-awards-for-entrepreneurial-success-and-innovation-in-biopharma-rd-302436301.html
SOURCE DeuteRx LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 hours ago
- Yahoo
Engineering the Perfect Shower Squeegee: The Story Behind dancemoon JustHang Squeegee
NEW YORK, June 7, 2025 /PRNewswire/ -- dancemoon, the trailblazer in home cleaning innovation, proudly introduced its first-ever bathroom cleaning tool: the JustHang Squeegee. Designed for effortless use and stylish storage, the product officially launched worldwide on June 3 via dancemoon's website and Amazon, debuting at a special launch price of $19.99. It has been well-received on social media for its outstanding performance and uniquely innovative built-in hook, and has continued to gain traction on Amazon and the official website since its initial launch. What sets the JustHang Squeegee apart is the thoughtful design, inspired by the simple and universal natural habit of hanging things up after use. Through rounds of real-life testing and countless small tweaks, the dancemoon team turned this everyday habit into a clean, minimalist solution that blends form and function. And behind this seemingly simple tool is a deliberate design process worth sharing. How It's Made: Integrated Molded Structure: The built-in hook of JustHang Squeegee isn't a traditional after-assembly attachment. Instead, it is molded by one-piece injection molding. This process reduces breakage risk at joints, maintains minimalist lines and structural stability, prevents dirt buildup and avoids discoloration over time. The handle uses glass fiber reinforced PA66 and the scraper blade is made of hardened 45 steel, offering excellent strength and heat resistance, enabling JustHang Squeegee to withstand up to 75kg pressure without breaking. Size and Angle Validation: Based on user habit research, dancemoon designers analyzed common hanging points and user behaviors in the bathroom. Through multiple prototype tests and hanging simulations, the size and angle of the built-in hook were finely adjusted to ensure that it can be firmly fixed in places such as towel bars, glass doors and countertops, and perfectly fit the user's natural "use and hang" action. Premium Flexible Silicone: Made from high-elasticity 50 Shore A silicone, this material offers an ideal balance of flexibility and structural strength. After extensive durability testing, the dancemoon design team selected this specific hardness for its outstanding performance in wet and slippery environments, resisting deformation and cracking even with prolonged use. The result is a smoother, more efficient water-wiping experience and a significantly longer lifespan compared to traditional squeegees. Why JustHang Squeegee? Convenience: Effortless to hang anywhere even with wet hands. Versatility: Designed to fit seamlessly into various home settings, offering clean, clutter-free storage. Durability: One-piece molded construction minimizes breakage and lasts longer than traditional scrapers. To place an order, please visit dancemoon's Amazon store and Shopify. Or follow dancemoon on social media to stay updated with the latest campaigns for the new product: Instagram: Facebook: YouTube: About dancemoon Driven by a passion for innovative design, dancemoon infuses the beauty and emotion of the moon into each product. Beyond offering household tools, dancemoon combines innovation with minimalist design to create products that make household tasks simple and no longer a burden but an enjoyable part of life. With a vision to become the leading brand of minimalist lifestyle, dancemoon is committed to blending minimalism with household tools, bringing bliss into your daily life. CONTACT: info@ View original content to download multimedia: SOURCE dancemoon
Motor Trend
a day ago
- Motor Trend
Hyundai's Hydrogen Fuel Cell Technology - Episode 45
© 2025 MotorTrend | MOTOR TREND GROUP, LLC. ALL RIGHTS RESERVED. Hearst Autos, Inc. recently acquired the website and MotorTrend mobile application from Warner Bros. Discovery. During a transition period, your use of the website and mobile application will continue to be governed by the practices described in the Warner Bros. Discovery Privacy Policy and the Terms of Use
Yahoo
a day ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
